MAPK3 and cervical carcinoma: All of the cervical cancer cells subjected to FR180204 treatment grew much more slowly (Figures 6C–F, p<0.05) and expressed less ERK1/2, p-ERK1/2, cyclin A1, and c-myc and more p27 (Figures 6A, B, p<0.05).